Efficacy of therapy with "Clopidogrel", extended (CYP2C19*2, *3, *17)

A genetic study that allows determining the efficacy of the use of the drug "Clopidogrel" based on the activity of the CYP2C19 enzyme. It is used for the personalized selection of antiaggregants for patients, predicting the efficacy of the drug for the prevention of atherothrombotic complications in patients who have suffered myocardial infarction, ischemic stroke, or with diagnosed occlusive peripheral artery disease, predicting the efficacy of the drug in patients with acute coronary syndrome (without ST-segment elevation (unstable angina or myocardial infarction without Q wave), including patients who underwent stenting during percutaneous coronary intervention, as well as in patients with ST-segment elevation (acute myocardial infarction) under medical treatment and the possibility of thrombolysis. Examination results are provided with interpretation.

Within 7 days. The specified time does not include the day of biomaterial collection